Alumis (NASDAQ:ALMS) Sets New 12-Month High – What’s Next?

Alumis Inc. (NASDAQ:ALMS) shares hit a new 52-week high on Tuesday . The company traded as high as $22.30 and last traded at $18.8590, with a volume of 30153270 shares traded. The stock had previously closed at $8.31.

Key Stores Impacting Alumis

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Phase 3 success — Both ONWARD trials met all primary and secondary endpoints with high statistical significance; strong efficacy (PASI?90 ~65%, PASI?100 >40% at Week 24) and tolerability support a planned NDA H2 2026. GlobeNewswire Release
• Positive Sentiment: Strong market reaction — The clinical news triggered heavy intraday volume and a large price move, reflecting investor reassessment of ALMS’s commercial and valuation prospects. Benzinga
• Positive Sentiment: Competitive positioning — Company statements and media coverage position envudeucitinib as a leading next?generation oral therapy in plaque psoriasis, potentially challenging larger incumbents. Schaeffer’s Research
• Neutral Sentiment: Conference call & webcast — Management hosted a conference call/webcast to discuss topline data and will post a replay; investors should listen for subgroup data, safety details and regulatory timeline color. QuiverQuant
• Neutral Sentiment: News flow confirmation — Major outlets (Reuters, Business Insider, TipRanks) corroborated the topline results; expect follow?up releases with full data and peer comparisons. Reuters
• Negative Sentiment: Execution & regulatory risk remains — NDA filing targeted H2 2026 but approval is not guaranteed; full datasets, long?term safety, and label/commercial positioning will determine ultimate value.
• Negative Sentiment: Financials & valuation risk — Alumis remains a pre?commercial, unprofitable company with recent quarterly revenue and EPS misses; a successful approval still requires scaling commercialization and justifying current market cap.

Analyst Upgrades and Downgrades

ALMS has been the topic of a number of recent research reports. Wall Street Zen raised Alumis from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Alumis in a research report on Monday, December 29th. HC Wainwright increased their price objective on Alumis from $14.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Finally, Wells Fargo & Company reiterated an “overweight” rating on shares of Alumis in a research report on Tuesday. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Alumis presently has an average rating of “Moderate Buy” and a consensus price target of $20.40.

Alumis Stock Up 107.3%

The firm has a fifty day moving average price of $8.16 and a 200-day moving average price of $5.53. The firm has a market cap of $1.80 billion, a price-to-earnings ratio of -4.28 and a beta of -2.09.

Alumis (NASDAQ:ALMS) last released its earnings results on Thursday, November 13th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.14). The company had revenue of $2.07 million during the quarter, compared to analysts’ expectations of $3.14 million. Equities research analysts anticipate that Alumis Inc. will post -8.51 earnings per share for the current fiscal year.

Insider Activity at Alumis

In related news, major shareholder Foresite Capital Management Vi bought 200,000 shares of the stock in a transaction that occurred on Monday, November 17th. The stock was purchased at an average cost of $5.59 per share, for a total transaction of $1,118,000.00. Following the completion of the acquisition, the insider owned 2,234,129 shares in the company, valued at $12,488,781.11. This trade represents a 9.83% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Srinivas Akkaraju purchased 276,179 shares of the company’s stock in a transaction that occurred on Thursday, November 13th. The shares were bought at an average cost of $5.25 per share, with a total value of $1,449,939.75. Following the transaction, the director directly owned 276,179 shares of the company’s stock, valued at $1,449,939.75. The trade was a ? increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders purchased 2,788,875 shares of company stock worth $18,352,357. 40.70% of the stock is owned by insiders.

Hedge Funds Weigh In On Alumis

Hedge funds have recently made changes to their positions in the stock. Samsara Biocapital LLC grew its stake in shares of Alumis by 47.0% during the 2nd quarter. Samsara Biocapital LLC now owns 4,801,370 shares of the company’s stock valued at $14,404,000 after buying an additional 1,534,872 shares during the period. Foresite Capital Management VI LLC grew its position in Alumis by 1.1% during the second quarter. Foresite Capital Management VI LLC now owns 4,247,670 shares of the company’s stock valued at $12,743,000 after acquiring an additional 45,000 shares during the period. Vanguard Group Inc. grew its position in Alumis by 18.4% during the third quarter. Vanguard Group Inc. now owns 4,029,615 shares of the company’s stock valued at $16,078,000 after acquiring an additional 625,404 shares during the period. Trium Capital LLP increased its stake in Alumis by 17.9% during the third quarter. Trium Capital LLP now owns 3,122,111 shares of the company’s stock worth $12,457,000 after acquiring an additional 474,072 shares during the last quarter. Finally, Orbimed Advisors LLC purchased a new position in shares of Alumis in the 2nd quarter worth about $5,779,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.